Considerations in Adapting Clinical Trial Design

The concept of adaptation of trial design during the course of a clinical trial has recently drawn much interest from the pharmaceutical industry. The interest arises partly because statistical decision trees employed to address multiple complex clinical hypotheses within a clinical trial are increa...

Full description

Bibliographic Details
Main Author: H.M. James Hung
Format: Article
Language:English
Published: Elsevier 2008-12-01
Series:Journal of the Formosan Medical Association
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664609600048
id doaj-42c920de4f504fb79e66852cb541cbea
record_format Article
spelling doaj-42c920de4f504fb79e66852cb541cbea2020-11-25T00:09:18ZengElsevierJournal of the Formosan Medical Association0929-66462008-12-0110712S14S1810.1016/S0929-6646(09)60004-8Considerations in Adapting Clinical Trial DesignH.M. James HungThe concept of adaptation of trial design during the course of a clinical trial has recently drawn much interest from the pharmaceutical industry. The interest arises partly because statistical decision trees employed to address multiple complex clinical hypotheses within a clinical trial are increasingly complex, and the statistical information generated from learning data prior to designing the trial is often insufficient to provide informative guidance for planning a pivotal trial. While the conventional fixed designs, which usually permit no modification influenced by the internal trial data of key design specifications, often cannot cover the range of complex statistical decision trees that must be prespecified in the study protocol, it seems natural to consider modifications of trial design at some point in the trial. In regulatory practice, some adjustments to study protocols are mostly made known to regulatory agencies in the form of so-called protocol amendments. However, such design modifications may demand careful consideration in dealing with any biases that may be caused by the adaptation, and may impede the interpretability of trial results.http://www.sciencedirect.com/science/article/pii/S0929664609600048adaptive designalpha spendingfixed designgroup sequential designlogisticstrial conduct
collection DOAJ
language English
format Article
sources DOAJ
author H.M. James Hung
spellingShingle H.M. James Hung
Considerations in Adapting Clinical Trial Design
Journal of the Formosan Medical Association
adaptive design
alpha spending
fixed design
group sequential design
logistics
trial conduct
author_facet H.M. James Hung
author_sort H.M. James Hung
title Considerations in Adapting Clinical Trial Design
title_short Considerations in Adapting Clinical Trial Design
title_full Considerations in Adapting Clinical Trial Design
title_fullStr Considerations in Adapting Clinical Trial Design
title_full_unstemmed Considerations in Adapting Clinical Trial Design
title_sort considerations in adapting clinical trial design
publisher Elsevier
series Journal of the Formosan Medical Association
issn 0929-6646
publishDate 2008-12-01
description The concept of adaptation of trial design during the course of a clinical trial has recently drawn much interest from the pharmaceutical industry. The interest arises partly because statistical decision trees employed to address multiple complex clinical hypotheses within a clinical trial are increasingly complex, and the statistical information generated from learning data prior to designing the trial is often insufficient to provide informative guidance for planning a pivotal trial. While the conventional fixed designs, which usually permit no modification influenced by the internal trial data of key design specifications, often cannot cover the range of complex statistical decision trees that must be prespecified in the study protocol, it seems natural to consider modifications of trial design at some point in the trial. In regulatory practice, some adjustments to study protocols are mostly made known to regulatory agencies in the form of so-called protocol amendments. However, such design modifications may demand careful consideration in dealing with any biases that may be caused by the adaptation, and may impede the interpretability of trial results.
topic adaptive design
alpha spending
fixed design
group sequential design
logistics
trial conduct
url http://www.sciencedirect.com/science/article/pii/S0929664609600048
work_keys_str_mv AT hmjameshung considerationsinadaptingclinicaltrialdesign
_version_ 1725412660145553408